Department of Gastroenterology, Hepatology and Nutrition, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA; Research Center of Gastroenterology and Hepatology, Craiova, Romania.
Sheikh Ahmed Pancreatic Cancer Research Center, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Gastrointest Endosc. 2021 May;93(5):1142-1151.e2. doi: 10.1016/j.gie.2020.09.051. Epub 2020 Oct 12.
EUS-guided FNA is recommended as a first-line procedure for the histopathologic diagnosis of pancreatic cancer. Molecular analysis of EUS-FNA samples might be used as an auxiliary tool to strengthen the diagnosis. The current study aimed to evaluate the diagnostic performances of K-ras testing using droplet digital polymerase chain reaction (ddPCR) and a novel single-nucleotide variant (SNV) assay performed on pancreatic EUS-FNA samples.
EUS-FNA specimens from 31 patients with pancreatic masses (22 pancreatic ductal adenocarcinomas, 7 chronic pancreatitis, and 2 pancreatic neuroendocrine tumors) were included in the study. K-ras testing was initially performed by ddPCR. In addition, mutational status was evaluated using an SNV assay by NanoString technology, using digital enumeration of unique barcoded probes to detect 97 SNVs from 24 genes of clinical significance.
The overall specificity and sensitivity of cytologic examination were 100% and 63%, respectively. K-ras mutation testing was performed using ddPCR, and the sensitivity increased to 87% with specificity 90%. The SNV assay detected at least 1 variant in 90% of pancreatic ductal adenocarcinoma samples; the test was able to detect 2 K-ras codon 61 mutations in 2 cases of pancreatic ductal adenocarcinoma, which were missed by ddPCR. The overall diagnostic accuracy of the cytologic examination alone was 74%, and it increased to 91% when the results of both molecular tests were considered for the cases with negative and inconclusive results.
The current study illustrated that integration of K-ras analysis with cytologic evaluation, especially in inconclusive cases, can enhance the diagnostic accuracy of EUS-FNA for pancreatic lesions.
EUS 引导下的 FNA 被推荐作为胰腺癌组织病理学诊断的一线方法。EUS-FNA 样本的分子分析可能被用作辅助工具来加强诊断。本研究旨在评估使用液滴数字聚合酶链反应 (ddPCR) 和在胰腺 EUS-FNA 样本上进行的新型单核苷酸变异 (SNV) 检测对 K-ras 检测的诊断性能。
本研究纳入了 31 例胰腺肿块患者(22 例胰腺导管腺癌、7 例慢性胰腺炎和 2 例胰腺神经内分泌肿瘤)的 EUS-FNA 标本。最初通过 ddPCR 进行 K-ras 检测。此外,使用 NanoString 技术的 SNV 检测评估突变状态,通过数字计数独特的条码探针来检测来自 24 个具有临床意义的基因的 97 个 SNV。
细胞学检查的总体特异性和敏感性分别为 100%和 63%。使用 ddPCR 进行 K-ras 突变检测,敏感性增加到 87%,特异性为 90%。SNV 检测在 90%的胰腺导管腺癌样本中至少检测到 1 个变体;该检测能够检测到 2 例胰腺导管腺癌中的 2 个 K-ras 密码子 61 突变,而 ddPCR 漏检了这两个突变。单独细胞学检查的总体诊断准确性为 74%,当将阴性和不确定结果的病例的两种分子检测结果结合考虑时,诊断准确性增加到 91%。
本研究表明,K-ras 分析与细胞学评估相结合,特别是在不确定的情况下,可以提高 EUS-FNA 对胰腺病变的诊断准确性。